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Abstract  
Over the past decade, second-generation antipsychotic medications have become the first-line treatment for 
schizophrenia. But efficacy of second generation antipsychotic compared with first generation antipsychotic in 
patients with schizophrenia has not been sufficiently addressed. The study objective was to perform a meta-
analysis of randomized trials compare the efficacy of second generation antipsychotic (SGAs) vs. first generation 
antipsychotics (FGAs). Searches were conducted for randomized, blinded studies comparing one or more of nine 
second- generation antipsychotics in the treatment of schizophrenia with first generation antipsychotic which 
published from 2003 till 2013 from nature, Pubmed central, and henari website. The primary outcome measure 
was change in total score on the Positive and Negative Syndrome Scale; secondary outcome measures were 
positive and negative symptom subs cores. The results were combined in comprehensive meta- analysis version 
2 software. The analysis included 9 studies, the meta-analysis comparing FGAs and SGAs using change in total 
PANSS, score, the odds ratio is 1.407 with 95 % confidence interval of 1.016-1.948 z- value of 2.055 and p-
value 0.04(p<0.05) indicating the result of analysis is statistically significant. The odds ratio is falls above 1 
indicating the patient treated with second generation antipsychotic were more likely reduce total PANSS score 
than first generation antipsychotic. In conclusion, Second generation antipsychotic is superior in reducing total 
PANSS score than first generation antipsychotic. Regard to resperidone and olanzapine, they are homogenous in 
reducing total PANSS score. 
Keywords: Efficacy, antipsychotic, second generation antipsychotic, first generation antipsychotic, PANSS 
score, meta-analysis. 
 
1. Introduction  
Schizophrenia is a heterogeneous syndrome characterized by perturbations of language, perception, thinking, 
social activity, affect, and volition. Schizophrenia has a worldwide prevalence of 1%; Schizophrenia causes 
social disability and also carries a high mortality. It has a strikingly high suicide rate of 10%, the early age at 
onset and its chronic nature means that schizophrenia is an expensive medical condition to health care systems 
and to society in general (Lean, Bchir, & Pajonk, 2003) (Brown, 2001) (Greens, Kern, & Heaton, 2004). 
Recovery" in schizophrenia must be defined as both functional (occupational & social) recovery as well as 
symptomatic recovery. Thus successful treatments for schizophrenia must show that they decrease: 
unemployment, social isolation, medical adverse effects, psychotic relapse, hospitalization, and suicide. 
Unfortunately, apart from antipsychotic medication, most of the other treatments for schizophrenia haven't 
consistently shown that they bring about both functional and symptomatic recovery. Early diagnosis and lifelong 
treatment on antipsychotic medication is absolutely essential for recovery from schizophrenia (Mental health, 
2013). 
The exact causes of schizophrenia and bipolar disorder are not fully known (Jones, et al., 2006). 
However, they are linked to changes in chemicals in the brain that influence behavior, mood, and thinking. The 
dopamine hypothesis of schizophrenia is the most fully developed theory of causation for this disorder, and until 
recently, it has been the foundation for the rationale underlying drug therapy for this disease. However, the 
dopamine hypothesis does not account for some important observations. If an abnormality of dopamine 
physiology were solely responsible for the pathogenesis of schizophrenia, antipsychotic drugs would do a much 
better job in treating patients. As it is, they are only partially effective for most and ineffective for some patients 
(Carpenter & Koenig, 2008) (Lasley, 2001). 
Antipsychotic medications are used to treat a number of psychiatric disorders, including schizophrenia, 
bipolar mania, dementia, and psychotic depression along with other drugs (AHRQ, 2010). Antipsychotics work 
by affecting chemicals involved in the pathogenesis of the disease. Antipsychotics are commonly categorized 
into two classes. First-generation antipsychotics (FGAs), also known as “typical antipsychotics,” were developed 
in the 1950s. Second-generation antipsychotics (SGAs), also known as “atypical antipsychotics,” emerged in the 
1980s. To date, FGAs have been classified according to their chemical structure, which includes serotonin-
dopamine antagonists and multi-acting receptor-targeted antipsychotics, whereas SGAs have been categorized 
according to their pharmacological properties as dopamine partial agonists (AHRQ, 2010) (Setta, et al., 2012).  
The first was the discovery of chlorpromazine, serendipitously, in 1952 in Paris by Laborit, Delay and Deniker, 
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who were the first to observe that this compound, which had been expected to be no more than a highly sedative 
antihistamine to relieve agitation, controlled delusions and hallucinations, and was, thus, the first antipsychotic 
drug . Numerous drugs with a similar mechanism of action were then quickly discovered (Meltzer, October 
2012). 
First-generation antipsychotics (FGAs), also known as neuroleptics or conventional antipsychotics, 
cause extrapyramidal side effects, including rigidity, bradykinesia, tremor, and akathisia (restlessness) most 
likely a few cases of neuroleptic malignant syndrome (NMS) . They also frequently lead to tardive dyskinesia—
hyperkinetic, involuntary movements most readily observed in the face and extremities. This would be especially 
true in elderly and post-menopausal patients (Potkin, Cohen, & Panagides, 2007). The antagonism of dopamine 
in the mesolimbic–mesocortical system is thought to be the basis of the therapeutic actions of these antipsychotic 
drugs, while antagonism of the nigrostriatal system is the major factor in the extrapyramidal side effects(EPS) 
seen with these agents (Ananth, Burgoyne, Gadasalli, & Aquino, 2001;) (Tuunainen, Wahlbeck, & Gilbody, 
2002 ) (Gründer, Hippius, & Carlsson, 2009).  
The prior concern with tardive dyskinesia as a result of neuroleptic treatment is diminished to some 
extent now that it is so rarely seen because of the introduction of, and near ubiquitous use of, atypical 
antipsychotic drugs (Potkin, Cohen, & Panagides, 2007). In addition to blocking 5-HT2A receptors Second 
generation also work by blocking D2 receptor but bind more loosely than dopamine to the dopamine D2 receptor 
and have dissociation constants higher than that for dopamine. Thus atypical antipsychotics clinically help 
patients by transiently occupying D2 receptors and then rapidly dissociating to allow normal dopamine 
neurotransmission. This keeps prolactin levels normal, spares cognition, and obviates EPS (Seeman, 2004). 
Though second generation antipsychotics  generally have lower risk of motor side effects, they  are 
associated with significant weight gain, elevated lipids and have been associated with the development of type 2 
diabetes, besides atypical antipsychotics are expensive comparing with the older agent (AHRQ, 2010).  
Increasing numbers of reports concerning diabetes, ketoacidosis, hyperglycaemia and lipid dysregulation in 
patients treated with second-generation (or atypical) antipsychotics have raised concerns about a possible 
association between these metabolic effects and treatment with these medications. Moreover, antagonism of 
dopamine’s neurohormonal action in the anterior pituitary accounts for the hyperprolactinemia associated with 
antipsychotic administration. Thus, the same pharmacodynamics action may have distinct psychiatric, 
neurological, and endocrinological outcomes (Newcomer, 2005). 
Atypical or second-generation antipsychotics (SGAs) were hailed as a major advance, principally 
because of their lower liability for EPSs. The first atypical drug, clozapine, is the most efficacious of all 
antipsychotics but is restricted to treatment resistant schizophrenia because of adverse effects. Over the past 
decade, second-generation antipsychotic medications have become the first-line treatment for schizophrenia 
(Rahman O. , 2011). 
Atypical antipsychotic drugs are more frequently used and prescribed to a great extent than typical 
antipsychotic drugs everywhere in the world. e.g. 18% in UK, 42% in Italy, 62% in USA but less than 2% in 
Palestine. According to other findings from the 2004–05 Medical Expenditure Panel Survey, an estimated 2 
million adult patients in the United States were prescribed an antipsychotic medication, three-quarters of whom 
were taking an SGA. In 2003, an estimated $2.82 billion were spent in the country on these medications, with 
SGAs accounting for 93 percent of this expenditure. There were some very interesting findings for these drugs’ 
use pattern. In one key finding, it has observed that most of the psychiatric patients were receiving atypical 
antipsychotics (61.46%) – either alone or in combination and this class is dominant in use in comparison to the 
typical antipsychotic drugs. Even single atypical antipsychotic drug was received by a large number of patients 
(23.44%) in comparison to typical antipsychotic single agent use (8.33%) (Jones, et al., 2006) (Setta, et al., 2012) 
(Rahman O. , 2011). 
The introduction of a second generation of antipsychotic drug has created a large literature concerning 
their therapeutic value and tolerability. Recently there has been concern over the reliability of this literature. The 
effects of pharmaceutical industry funding, publication bias, the appropriateness of first-generation comparators 
(particular haloperidol) and a range of other methodological issues have come under close scrutiny. Thus 
therapeutic differences between the other SGAs and FGAs are less certain (Terry, Goldberg, Robert, & Goldman, 
2007) (Leucht, Corves, Arbter, Engel, Li, & Davis, 2009). Two systematic reviews showed that the 2 groups of 
drugs are generally equivalent in terms of efficacy against positive symptoms, whereas another study found 
evidence of superiority for SGAs. Claims of superiority for SGAs in terms of the treatment of negative 
symptoms, cognitive enhancement, fewer EPSs, and improved subjective experience and tolerability have led to 
a general shift away from FGAs in the treatment of schizophrenia (Miller, 2004). 
However, no clear evidence that atypical antipsychotics are more effective or are better tolerated than 
typical antipsychotics. Consequently this meta-analysis compared the efficacy and safety of second-generation 
antipsychotics with a first-generation antipsychotic in the treatment of psychosis.  
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2. Method 
2.1. Selection and Study Characteristics  
In this study randomized control clinical trial of patients with psychosis is selected which  published from 2003 
till 2013 written in English that compare second generation antipsychotic with either first generation 
antipsychotics or another second generation antipsychotic and a dose response comparison of FGAs and SGAs.   
 
2.2. Literature Search Strategy  
The data bases which were searched for the free and full articles were nature, Pubmed central, and henari; the 
preferences for those data bases were the availability of free full articles and the existence of user name and 
password for the database website. In addition to these database literature were searched using Google search 
engines by using the following search terms; efficacy, second generation antipsychotic, second generation 
antipsychotic versus first generation antipsychotic and efficacy of antipsychotic.  
 
2.3. Exclusion criteria  
A study that was done before 2003 were not used as data source in this meta-analysis, in addition to this, articles 
not written in English and not free of charges are not included.  
 
2.4. Principal Outcome 
Odds ratios were calculated from the positive and negative syndrome scale (PANSS) or, when that was not 
available, total PANSS score is calculated by addition of its component from the addition of positive symptom 
sub-score, negative symptom sub-score and General Psychopathology scale. Heterogeneity was calculated to 
ensure that the outcome variable was reasonably normally distributed. 
 
2.5. Data collection 
Data were extracted from both text and tables of the original papers. 
 
2.6. Data Extraction 
The number of participant, the mean change in PANSS score, sample size and the mean change in positive and 
negative symptom sub-score data of all studies included in the meta- analysis were extracted. 
 
2.7. Statistical Analysis   
Statistical analysis was performed with comprehensive meta- analysis version 2 software which Compute the 
odds ratio automatically, perform the meta-analysis quickly and accurately create high-resolution forest plots. 
 
3. Result  
3.1. Description of Studies  
Twenty free and full randomized control trials study were selected from the initial search that compare first 
generation antipsychotics with second generation antipsychotics, five studies with no or inadequate 
randomization; four studies with no appropriate drug group and that used only groups of second generation do 
not include either resperidone or olanazapine ; and two studies with no usable data. The meta-analysis included 
nine studies among them six were used to compare typical and atypical antipsychotics and five were used to 
compare atypical resperidone with olanazapine. The studies used PANSS and other outcome measure for their 
comparison. 
Among the six randomized controlled trial selected for the comparison of first generation and second 
generation antipsychotics one trial were conducted in 2008; two trial conducted in 2006; one trial conducted  in 
2005; one trial conducted in 2004 and one trial conducted in 2003 [Table 1]. 
Five studies present data from different phases of the clinical antipsychotic Trials of intervention to 
conduct comparison between second generation antipsychotic resperidone and olanazapine [Table 2]. 
 
3.2. Results of the meta-analysis 
The meta-analysis comparing FGAs and SGAs using change in total PANSS, score, the odds ratio is 1.407 with 
95 % confidence interval of 1.016-1.948 z- value of 2.055 and p-value 0.04(p<0.05) indicating the result of 
analysis is statistically significant. The odds ratio is falls above 1 indicating the patient treated with second 
generation antipsychotic were more likely reduce total PANSS score than first generation antipsychotic[Fig 1]. 
The odds ratio of first-generation antipsychotic versus second-generation antipsychotic using only change in 
positive symptom sub score is shown in Figure 2. It should be noted the odds ratio is greater than one (1.319 
with 95% confidence interval of 0.717-2.427) but p-value is 0.373 > p-0.05 the difference in reduction of 
positive symptom sub score is not statistical significant. Similar result also observed on the meta- analysis using 
negative symptom sub score, odds ratio 1.195 with 95% confidence interval of 0.518-2.755 p- value 
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0.076(p>0.05) and z- value 0.417  Figure 3. 
The Meta analysis of resperidone versus olanazapine that included four studies shows a difference in 
change in total PANSS score but statistically is not significant p- value 0.157( p>0.05) .  The odds ratio is 1.397 
with 95% confidence interval of 0.879-2.221 and z- value is1.415. Similar result was found in comparing the two 
drugs using change in positive symptom sub score indicated odds ratio is 1.491 with 95 % confidence interval of 
0.795-2.797 p -value and z- value is 0.213(p>0.05) and 1.246 respectively which is not statistically significant. 
But using the outcome change in negative syndrome sub score the meta-analysis is in the favour of resperidone 
the analyzed odds ratio is 0.617 with 95% confidence interval of 0.290-1.311; p-value 0.209( P>0.05) and z- 
value is -1.256[ Figure 4, Figure 5 and Figure 6). 
 
4. Discussion 
The introduction of a second generation of antipsychotic drug has created a large literature concerning their 
therapeutic value and tolerability. Recently there has been concern over the reliability of this literature. In this 
meta-analysis first generation and second generation( typical and atypical) antipsychotics drugs and among 
atypical resperidone and olanazapine were compared using studies that uses PANSS score, positive symptom sub 
score and negative symptom sub score for their outcome measure.  
Randomized control trial (RCT) investigated efficacy through a variety of different outcome criteria 
like the positive and negative syndrome scale (PANSS), the brief psychiatric rating scale (BPRS) and the clinical 
global rating (CGR).  However, this meta-analysis uses the PANSS to compare groups of antipsychotic drugs as 
outcome criteria because the availability of this outcome measure in most study.    
The PANSS is used for measuring symptom severity following a 45-minute clinical interview with the 
patient and reviewing relevant reports from family members and hospital workers. Each of 30 symptoms is rated 
from 1 (absent) to 7 (extreme). Symptoms are grouped into three subscales: positive symptoms (i.e., delusions, 
conceptual disorganization, hallucinations, hyperactivity, grandiosity, suspiciousness or persecution, and 
hostility), negative symptoms (i.e., blunted affect, emotional withdrawal, poor rapport, passive or apathetic 
social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped 
thinking), and general psychopathology symptoms (i.e., somatic concern, anxiety, guilt feelings, tension, 
mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, 
disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, 
preoccupation, and active social avoidance). 
A study that was done in 2006 by Jones PB, et al. indicated that there is little difference between the 
two groups of drug and metal analysis done in 2003 by Davis JM et al. indicated in their work that there is 
difference between typical and atypical antipsychotic drugs and concluded that second generation antipsychotic 
superior than first generation antipsychotic (Jones, et al., 2006) (Davis, Chen, & Glick, 2003). The result of this 
meta-analysis consistent with Davis JM et al. the odds ratio is 1.407 with 95 % confidence interval of 1.016-
1.948 z- value of 2.055 and p-value 0.04(p<0.05). 
The older, typical neuroleptics are effective antipsychotic agents with neurologic side effects involving 
the extrapyramidal motor system. Typical neuroleptics block the dopamine-2 receptor. All atypical neuroleptics 
block dopamine and serotonin receptors; other neurochemical effects so that this additional serotonin receptor 
blockage may be given additional advantage for second generation antipsychotic to become superior to first 
generation antipsychotic in total change in PANSS score. Other explanations for the findings include the study 
participants in the first generation antipsychotic hand  was compared with out prophylactic anticholinergic , 
because some extrapyramidal side effects , described as akinesia or akinetic depression that are responsive to 
anticholinergic, can emerge without telltale parkinsonian features. Thus these symptoms can be indistinguishable 
from negative symptoms of schizophrenia this gives an unfair advantage to second generation antipsychotic 
(Rosenheck, Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without 
Anticholinergics as a Comparator, 2005) (Kahn, et al., 2008). 
In addition the meta-analysis comparing positive symptom sub score and negative symptom sub score  
is not statistical significant the odds ratio is greater than one (1.319 with 95% confidence interval of 0.717-2.427) 
but p-value is 0.373 > p-0.05. Similar result also observed on the meta- analysis using negative symptom sub 
score, odds ratio 1.195 with 95% confidence interval of 0.518-2.755 p- value 0.076(p>0.05) and z- value 0.417. 
PANSS include 30 assessment questions of which Of the 30 items included in the PANSS, 7 constitute a 
Positive Scale, 7 a Negative Scale and the remaining 16 a General Psychopathology Scale thus, the superiority of 
second generation may be due to general psychopathology scale and the analysis used only three studies. 
Regard to differences between the different second-generation antipsychotics, for example CATIE(C)  
and two  meta-analyses (Leucht, Corves, Arbter, Engel, Li, & Davis, 2009) (Davis, Chen, & Glick, 2003) 
conclude that there is small difference among the groups of atypical antipsychotics drugs and another study 
conclude that there were no differences between the treatment group with regards to PANSS score. In this meta-
analysis no significant differences in efficacy were noted among the different atypical agents (resperidone and 
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olanazapine) the odds ratio is 1.397 with 95% confidence interval of 0.879-2.221 and z- value is1.415. The 
pattern of outcomes in terms of positive symptoms sub score and negative symptom score paralleled that of the 
PANSS total score. 
In deciding on the choice of antipsychotic drugs for the treatment of psychosis not only the magnitude 
of the efficacy differences measured by reduced PANSS outcome other characteristics like medication cost, the 
appearance of side effect because the efficacy of a medication can be interpreted only in the context of its 
adverse effect profile and patient past response should be predetermined to obtain optimal benefit from the drug. 
Generally the focus of treatment with antipsychotics is no longer only symptom reduction alone, but well-being 
therapy and improvement of quality of life. And this study should be further strengthened by different studies 
using different rating scales. Variation in treatment evaluations using outcome measurement and patient 
populations across studies makes it difficult to draw well-founded conclusions from this meta-analysis  
 
5. Conclusion 
Second generation antipsychotic is superior in reducing total PANSS score than first generation antipsychotic. 
Regard to resperidone and olanzapine, they are homogenous in reducing total PANSS score. On the other hand 
the risks of weight gain and metabolic side effects with some second-generation antipsychotics needs of closely 
monitoring weight, glucose and lipid levels, and liver functioning. In general side effect, individual response and 
cost of a drug should be considered in addition to reduction the total PANSS score for the choice of 
antipsychotic drug. 
 
6. Recommendation  
Since PANSS is not the only indicator of efficacy of antipsychotic it is recommended to do another meta-
analysis using the brief psychiatric rating scale (BPRS) and, the clinical global rating with large number of 
studies to come with a better conclusion. And the choice should be an individual one based on the particular 
profiles of the individual drug and on the patient's preferences. 
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Table and figure Legends  
Table 1 Description of studies selected for the comparison of first generation and second    generation 
antipsychotics drug. 
Serial 
Number 
 
Author 
Participants  
Follow Up Periods FGAS SGAS 
1 (Jones, et al., 2006) 99 86 52 weeks 
2 (Sikich, et al., 2008) 40 76 8 weeks 
3 (Schooler, et al., 2005) 264 264 30 weeks 
4 (Lieberman, et al., 2003) 132 131 12 weeks 
5 (Rosenheck, et al., 2006) 256 1168 18 months 
6 (Keefe, et al., 2004) 78 89 12 weeks 
 
Table 2  Description of studies selected for the comparison of two second generation antipsychotics resepridone 
vs olanazapine. 
Serial 
Number 
 
Author 
Participants Follow Up Periods 
Resperidone Olanazapine 
1 (Rosenheck, et al., 2006) 332 328 18 months 
2 (Sikich, et al., 2008) 41 35 8 weeks 
3 (Sevy, et al., 2011) 21 28 16 weeks 
4 (Stroup, et al., 2007) 38 39 15 months 
5 (McEvoy, et al., 2007) 37 37 52 weeks 
 
Figure 1  A meta-analysis of first generation antipsychotics VS Second generation antipsychotics, outcome: 
change in total PANSS score 
 
Figure 2   A meta-analysis of first generation antipsychotics VS second generation antipsychotics, outcome: 
change in positive symptom sub-score 
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Figure 3  A meta-analysis of first generation antipsychotics VS second generation antipsychotics, outcome: 
change in negative symptom subs-score 
 
Figure 4  A meta-analysis of first generation resperidone VS olanazapine, outcome: change in total PANSS 
score 
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Figure 5  A meta-analysis of resperidone VS olanazapine, outcome: change in positive symptom sub-score 
 
Figure 6  A meta-analysis or resperidone VS olanzapine: change in negative symptom sub-score  
